ERS Genomics, an Irish biotechnology firm, has appointed Eric Rhodes as its new chief executive officer.
He replaces co-founder Shaun Foy in the lead role, who will continue on with the company as chairman of the board.
Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer.
In these roles, Rhodes was responsible for commercialising the company’s genome editing technologies as well as driving its research and development.
Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo Biosciences.
Foy said: “With his deep understanding of the gene-editing landscape and extensive experience in marketing and commercialising gene-editing technologies, Eric is a perfect fit to help ERS Genomics accelerate our commercialisation activities.
“We are excited to welcome him to the team.”